Gene to Health Limited Team Profile

Team Profile

Company website: https://gene2h.com

Under the guidance of Prof. Pak Sham, Gene to Health Limited was founded in October 2022 with Dr. Chen Guolan as the founding CEO and Dr. Justin Tubbs as confounder and former CTO. The company is currently undergoing a three-year incubation at the Hong Kong Science and Technology Parks Corporation (HKSTP). The company develops multi-omics prediction technology with polygenic risk scoring as the core, with the goal of predicting, early screening and auxiliary diagnosis of various common and complex diseases such as childhood autism, Alzheimer's, depression, type 2 diabetes, hypertension, coronary artery disease, etc., combined with the AI-assisted virtual genetic counseling platform.

The laboratory's research focuses on the intersection of statistical genetics, machine learning, genomics, and bioinformatics. Dr. Chen's research focuses on the application of multiple regular regression and Bayesian models to genomic big data mining of disease cohorts to achieve fine mapping of pathogenic genes in complex diseases and analysis of genetic structure of phenotypic groups. Dr. Chen holds a bachelor's degree in biostatistics from the School of Life Sciences of Fudan University, and recently graduated from the Department of Psychiatry of the Faculty of Medicine of the University of Hong Kong in 2024 under the supervision of Professor Pak Sham, a world-renowned human geneticist (with more than 150,000 citations). The R&D scientists in the team are proficient in IT development and data science skills such as R language, Python, html5, database, cloud computing, etc., and are good at handling high-dimensional data analysis and complex model construction. The entrepreneurial team has accumulated rich experience in bioinformatics, genomics, and multimodal data analysis, and is committed to promoting the interdisciplinary application of biotechnology and pharmaceutical innovation.

Gene to Health Limited is the first in Asia to develop a practical application of polygenic scoring technology based on millions of disease-related genetic variant data, which can predict more than 800 traits and diseases at an early stage, and is now developing from the positioning of health management products to the clinical direction. We provide ultra-early and full-coverage disease and phenotype prediction services through genetic testing combined with questionnaires, nutritional data, physical examinations and medical records, proteomics and metabolomics data, etc., so that people can obtain a variety of health management and medical benefits, and ultimately help early screening, auxiliary diagnosis and early intervention of diseases. The technologies used by the company include statistical modeling, machine learning, big data analysis, epidemiological analysis, bioinformatics, database development, and AI large language model development.

Introduction to our core products

Our core product suite is an integrated intelligent genetic prediction technology platform called Gene-to-Health (G2H). Trained on genomic research data (open data) from millions of people, the platform is able to make predictions about various human traits and common diseases based on an individual's genetic data (DNA variation information). This genetic data is easily available from test kits sold by most direct-to-consumer genetic testing vendors (e.g., Microgenetics, 23 Rubik's Cube). G2H provides more than just disease risk analysis; Combined with the generative AI model, it actually acts as a virtual genetic counselor, analyzing and explaining the customer's genetic test report through question-and-answer interaction, and providing intelligent and personalized nutrition, prevention and intervention suggestions. At present, our platform is used by enterprise users in the gene industry for product development and scientific research services.

The cost of genetic testing has rapidly decreased and is currently affordable (hundreds to thousands of RMB) for most people. However, the effectiveness and benefits of all currently commercially available test kits in terms of healthcare are relatively weak. Most consumers don't feel the benefits because even well-known providers such as 23AndMe, Ancestry, and Microgene have very limited information about their personal health information. In order to attract more customers, the G2H platform can help them provide comprehensive healthcare prediction and fertility consultation advice services, adding a very attractive selling point. We envision that in the near future, people will be able to understand their (and their children's) future risk of developing common diseases for a single test that will not only be lifelong, but will always be updated with the accumulation of big data and technological advancements.

The G2H platform is designed to help users optimize their lifestyles, prevent and manage related diseases, and improve their overall health by using advanced genomics analysis, personalized nutrition solutions, and health management systems in the following four areas:

1. Risk assessment and management of common diseases:
   Based on genetic data, physical examination reports, and lifestyle information, the G2H platform conducts risk assessment of common chronic diseases such as cardiovascular diseases, diabetes, and hypertension, and provides personalized health intervention suggestions according to the specific risk level of users. Through regular monitoring and precise management, the platform effectively helps users reduce the risk of disease and improve their quality of life.
2. Diet and Nutrition Optimization:
   The G2H platform provides users with personalized dietary recommendations through in-depth analysis of individual genomes combined with accurate nutritional data, optimizes nutritional intake, and prevents diet-related chronic diseases, such as obesity, diabetes, and hypertension. The platform can also provide scientific dietary adjustment suggestions and recommended nutritional supplement plans by combining the dietary behavior and nutrient intake information provided by users.
3. Skin health management:
   By analyzing users' genetic data, the G2H platform is able to identify genetic variants associated with skin aging, sensitivities, and diseases such as eczema and psoriasis. Combined with accurate skin care suggestions and lifestyle adjustments, we provide users with skin health management solutions and skin care product recommendations to delay aging, improve skin condition, and prevent the occurrence of skin diseases.
4. Cancer risk prediction and intervention:
   Using mutant gene detection and big data analysis, the G2H platform provides users with personalized cancer risk predictions, especially for cancer types that are closely related to genetic genes (such as breast cancer and colon cancer). The platform combines nutrition, exercise and lifestyle interventions to provide scientific prevention and early screening recommendations.

Through these specialized applications, the G2H platform provides users with a full range of health management support, helping everyone achieve a healthier and better life.

In addition to G2H's platform, the company has built other R&D pipelines:

1)     An intelligent genomic breeding screening platform for agricultural breedin (genomics-for-breeding, G4B);

2)     G2H-Pet and G4B-Pet for Pet (Cat and Dog) Disease Prediction and Breeding;

3)     Genome-based multi-omics prediction and diagnosis tools for degenerative diseases such as Alzheimer's and Parkinson's disease;

4)     Genome-guided medication consultation tool for breast cancer patients.

The above pipelines are all in the early stage of research and development or concept verification.

Company vision

Represented by the UK Biobank and the All of US cohort, the "Population Genome Project" and "Large Cohort", which are characterized by the simultaneous acquisition of genomic (multi-omics)-phenotype data of large samples in the same population, are emerging in countries around the world. These cohorts often have sample sizes ranging from hundreds of thousands to millions of people. The health information contained in genetic big data is a valuable resource for every group of people and nations, and is an indispensable part of building population health, precision medicine and good preventive medicine. As the world's most populous country and a multi-ethnic country, China is also striving for the top, and various scientific research units are uniting to promote the construction and development of the Chinese population. The company's long-term vision is to lay the infrastructure for the construction of the large fleet of Chinese people, and to do a good job in the development and preparation of research design and tools, software and algorithms, operation management and systems.

Prospects for cooperation

Our G2H platform can be specialized and tuned for the prediction and evaluation of specific directions and types of diseases, such as cardiovascular disease prediction. We have created a sample version that does not require genetic data, aiming to help users assess the risk of cardiovascular disease (including heart attack and stroke) in the next 10 years through advanced genomic analysis and a variety of authoritative risk assessment methods based on questionnaire data, providing a scientific basis for health management and medical interventions. Try our demo and get your own report in English or Chinese for free at https://g2h.lanechen.xyz

Because the G2H platform covers more than 800 phenotypes and diseases, there is a huge potential for collaboration with partners who specialize in different areas by collaborating on the development of specialized applications.

We can further improve the adaptability and scalability of the G2H platform through modular design and flexible interfaces, enabling it to quickly integrate algorithms and data sources from different domains. For example, partners can combine their own datasets and algorithms to work with our platform to develop customized solutions for specific populations, specific diseases, or specific scenarios. This open cooperation model can not only quickly respond to market demand, but also promote multi-party resource sharing and technological innovation.

In addition, the G2H platform has strong data privacy protection capabilities, and ensures the security and compliance of user data through advanced encryption technology and de-identification processing. This makes the platform more advantageous in the field of healthcare, and can provide reliable data processing and analysis support for medical institutions, scientific research teams and business partners.

In the future, we will further expand the application scope of the G2H platform, such as developing more efficient and accurate assessment tools for metabolic diseases, psychiatric diseases, geriatric diseases, neurological diseases and tumor risk prediction.

Looking forward to working with you!

If you are interested in further negotiation or more information, please contact us:

       •     Contact information of CEO Dr. Chen Guolan

Email：lanechenhku@gmail.com;

WeChat：lane13318032043;

WhatsApp: +852 46404365

       •     Company Email:support@gene2h.com

       •     Official Website:www.gene2h.com